A Phase I Pilot Study of Immunotherapy Using Lenalidomide Plus 'Bystander' Vaccine in Patients With High-Risk Myelodysplastic Syndrome (MDS).

Trial Profile

A Phase I Pilot Study of Immunotherapy Using Lenalidomide Plus 'Bystander' Vaccine in Patients With High-Risk Myelodysplastic Syndrome (MDS).

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs CD40L GVAX (Primary) ; Lenalidomide (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 23 Jan 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top